Conferences
Conferences
Advertisement
Patrick DalyConferences | September 15, 2023
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Read More
Patrick DalyConferences | September 15, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Patrick DalyConferences | September 15, 2023
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Patrick DalyConferences | September 15, 2023
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
Dustin SamplesConferences | September 13, 2023
It is important to monitor patients who have elevated CMV levels to detect infection and progression early.
Dustin SamplesConferences | September 13, 2023
Results from this meta-review suggest that more prophylactic strategies are needed in the fight against GVHD.
Dustin SamplesConferences | September 13, 2023
Intensive salvage therapy had a 54% complete remission rate whereas non-intensive salvage therapy was lower at 18%.
Dustin SamplesConferences | September 8, 2023
The study used only single-agent tacrolimus for GVHD prophylaxis.
Dustin SamplesConferences | September 8, 2023
Non-relapse mortality was low, and there was good GVHD control with the prophylaxis.
Dustin SamplesConferences | September 8, 2023
Results were further improved when Orca-T was given in combination with a regimen of busulfan, fludarabine, and thiotepa.
Cailin ConnerConferences | September 8, 2023
Limited diagnostic resources, such as EPO level tests, can result in late or misdiagnosis and increased health care costs.
Cailin ConnerConferences | September 8, 2023
The average cost of hospitalization for a TE was $4000-9000 higher than for generally medically ill patients.
Cailin ConnerConferences | September 8, 2023
Investigators noted improved spleen size and blood parameters in addition to improvement in PV symptoms.
Dustin SamplesConferences | September 8, 2023
Rusfertide improved response maintenance and reduced the need for therapeutic phlebotomy.
Dustin SamplesConferences | September 6, 2023
Findings from this pilot study suggest that EVs may be a promising avenue for developing ocular GvHD therapies.
Dustin SamplesConferences | September 6, 2023
Differences in microRNA expression could help identify individuals at risk of developing GVHD.
Dustin SamplesConferences | September 6, 2023
Despite advances in understanding GVHD, outcomes remain poor for patients with T-PLL.
Dustin SamplesConferences | September 6, 2023
There was no increased risk of graft-versus-host disease with earlier administration.
Dustin SamplesConferences | September 6, 2023
The drug also did not appear to increase the risk of GVHD, though it did improve symptoms in 2 patients.
Dustin SamplesConferences | September 6, 2023
The study authors noted that PTCy-based prophylaxis provided reasonable GVHD control but did not affect OS or GRFS.
Advertisement
Advertisement
Advertisement